{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T07:22:02Z","timestamp":1790061722010,"version":"4.0.1"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Critical Care"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.jcrc.2019.07.008","type":"journal-article","created":{"date-parts":[[2019,7,10]],"date-time":"2019-07-10T19:20:16Z","timestamp":1562786416000},"page":"77-82","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Optimal vancomycin dosing regimens for critically ill patients with acute kidney injury during continuous renal replacement therapy: A Monte Carlo simulation study"],"prefix":"10.1016","volume":"54","author":[{"given":"Taniya","family":"Charoensareerat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weerachai","family":"Chaijamorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apinya","family":"Boonpeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nattachai","family":"Srisawat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chalermsri","family":"Pummangura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sutthiporn","family":"Pattharachayakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jcrc.2019.07.008_bb0005","doi-asserted-by":"crossref","first-page":"R47","DOI":"10.1186\/cc6863","article-title":"Early acute kidney injury and sepsis: a multicentre evaluation","volume":"12","author":"Bagshaw","year":"2008","journal-title":"Crit Care"},{"issue":"Suppl. 1","key":"10.1016\/j.jcrc.2019.07.008_bb0010","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1186\/cc7003","volume":"12","author":"Kolhe","year":"2008","journal-title":"Crit Care"},{"issue":"6","key":"10.1016\/j.jcrc.2019.07.008_bb0015","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1097\/01.CCM.0000217961.75225.E9","article-title":"Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock","volume":"34","author":"Kumar","year":"2006","journal-title":"Crit Care Med"},{"issue":"8","key":"10.1016\/j.jcrc.2019.07.008_bb0020","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1097\/CCM.0000000000000330","article-title":"Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program","volume":"42","author":"Ferrer","year":"2014","journal-title":"Crit Care Med"},{"issue":"4","key":"10.1016\/j.jcrc.2019.07.008_bb0025","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/sdi.12496","article-title":"We Underdose antibiotics in patients on CRRT","volume":"29","author":"Shaw","year":"2016","journal-title":"Semin Dial"},{"issue":"1","key":"10.1016\/j.jcrc.2019.07.008_bb0030","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/01.CCM.0000190243.88133.3F","article-title":"Pharmacokinetics and total elimination of meropenem and vancomycin in intensive care unit patients undergoing extended daily dialysis","volume":"34","author":"Kielstein","year":"2006","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jcrc.2019.07.008_bb0035","series-title":"Principles and practice of dialysis","author":"Henrich","year":"2009"},{"issue":"6","key":"10.1016\/j.jcrc.2019.07.008_bb0040","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/clpt.1991.208","article-title":"Vancomycin pharmacokinetics in acute renal failure: preservation of nonrenal clearance","volume":"50","author":"Macias","year":"1991","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.jcrc.2019.07.008_bb0045","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1053\/ajkd.1998.v31.pm9631848","article-title":"Determinants of vancomycin clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis","volume":"31","author":"Joy","year":"1998","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"10.1016\/j.jcrc.2019.07.008_bb0050","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1086\/444500","article-title":"Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy","volume":"41","author":"Trotman","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jcrc.2019.07.008_bb0055","series-title":"Physicians ACo. Drug prescribing in renal failure : dosing guidelines for adults and children","author":"Aronoff","year":"2007"},{"issue":"5","key":"10.1016\/j.jcrc.2019.07.008_bb0060","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1592\/phco.29.5.562","article-title":"Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis","volume":"29","author":"Heintz","year":"2009","journal-title":"Pharmacother"},{"issue":"2","key":"10.1016\/j.jcrc.2019.07.008_bb0065","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ijantimicag.2011.04.010","article-title":"Vancomycin clearance during continuous venovenous haemofiltration in critically ill patients","volume":"38","author":"Chaijamorn","year":"2011","journal-title":"Int J Antimicrob Agents"},{"issue":"12","key":"10.1016\/j.jcrc.2019.07.008_bb0070","doi-asserted-by":"crossref","first-page":"6181","DOI":"10.1128\/AAC.00459-12","article-title":"Effect of continuous venovenous hemofiltration dose on achievement of adequate vancomycin trough concentrations","volume":"56","author":"Frazee","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.jcrc.2019.07.008_bb0075","doi-asserted-by":"crossref","first-page":"329","DOI":"10.5414\/CN106993","article-title":"Vancomycin levels are frequently subtherapeutic during continuous venovenous hemodialysis (CVVHD)","volume":"77","author":"Wilson","year":"2012","journal-title":"Clin Nephrol"},{"issue":"1","key":"10.1016\/j.jcrc.2019.07.008_bb0080","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01684-17","article-title":"Identification of vancomycin exposure-toxicity thresholds in hospitalized patients receiving intravenous vancomycin","volume":"62","author":"Zasowski","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.jcrc.2019.07.008_bb0085","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.ijantimicag.2018.08.024","article-title":"Implementation of a two- point pharmacokinetic AUC-based vancomycin therapeutic drug monitoring approach in patients with methicillin-resistant Staphylococcus aureus bacteraemia","volume":"52","author":"Mogle","year":"2018","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"10.1016\/j.jcrc.2019.07.008_bb0090","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1086\/600884","article-title":"Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients","volume":"49","author":"Lodise","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.jcrc.2019.07.008_bb0095","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02535-16","article-title":"Establishment of an AUC0-24 threshold for nephrotoxicity is a step towards individualized vancomycin dosing for methicillin-resistant Staphylococcus aureus bacteremia","volume":"61","author":"Chavada","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.jcrc.2019.07.008_bb0100","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02042-17","article-title":"Prospective trial on the use of trough concentration versus area under the curve to determine therapeutic vancomycin dosing","volume":"62","author":"Neely","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jcrc.2019.07.008_bb0105","author":"International Society of Nephrology (ISN)"},{"issue":"6","key":"10.1016\/j.jcrc.2019.07.008_bb0110","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/BF01694710","article-title":"Pharmacokinetics of vancomycin during continuous hemodiafiltration","volume":"19","author":"Santre","year":"1993","journal-title":"Intensive Care Med"},{"issue":"10","key":"10.1016\/j.jcrc.2019.07.008_bb0115","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1007\/s001340051018","article-title":"Vancomycin clearance during continuous venovenous haemofiltration in critically ill patients","volume":"25","author":"Boereboom","year":"1999","journal-title":"Intensive Care Med"},{"issue":"11","key":"10.1016\/j.jcrc.2019.07.008_bb0120","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1007\/s00134-002-1495-z","article-title":"Clearance of vancomycin during high-volume haemofiltration: impact of pre-dilution","volume":"28","author":"Uchino","year":"2002","journal-title":"Intensive Care Med"},{"issue":"3","key":"10.1016\/j.jcrc.2019.07.008_bb0125","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1365-2125.2004.02143.x","article-title":"Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltration","volume":"58","author":"DelDot","year":"2004","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.jcrc.2019.07.008_bb0130","doi-asserted-by":"crossref","first-page":"65","DOI":"10.5507\/bp.2012.092","article-title":"Vancomycin pharmacokinetics during high-volume continuous venovenous hemofiltration in critically ill septic patients","volume":"158","author":"Petejova","year":"2014","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"issue":"6","key":"10.1016\/j.jcrc.2019.07.008_bb0135","first-page":"645","article-title":"Drug dosing in continuous renal replacement therapy: general rules","volume":"13","author":"Schetz","year":"2007","journal-title":"Curr Opin Crit Care"},{"key":"10.1016\/j.jcrc.2019.07.008_bb0140","first-page":"1","article-title":"Improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury","volume":"2","author":"Kidney Disease","year":"2012","journal-title":"Kidney Int Suppl"},{"issue":"1","key":"10.1016\/j.jcrc.2019.07.008_bb0145","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00134-012-2706-x","article-title":"Management of renal replacement therapy in ICU patients: an international survey","volume":"39","author":"Legrand","year":"2013","journal-title":"Intensive Care Med"},{"issue":"4","key":"10.1016\/j.jcrc.2019.07.008_bb0150","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1053\/j.ajkd.2016.03.427","article-title":"Continuous Dialysis therapies: Core curriculum 2016","volume":"68","author":"Macedo","year":"2016","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1016\/j.jcrc.2019.07.008_bb0155","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s41100-016-0055-x","article-title":"In silico trials using Monte Carlo simulation to evaluate ciprofloxacin and levofloxacin dosing in critically ill patients receiving prolonged intermittent renal replacement therapy","volume":"2","author":"Lewis","year":"2016","journal-title":"Ren Replace Ther"},{"issue":"10","key":"10.1016\/j.jcrc.2019.07.008_bb0160","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1002\/jcph.727","article-title":"Use of Monte Carlo simulations to determine optimal carbapenem dosing in critically ill patients receiving prolonged intermittent renal replacement therapy","volume":"56","author":"Lewis","year":"2016","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.jcrc.2019.07.008_bb0165","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2146\/ajhp080434","article-title":"Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists","volume":"66","author":"Rybak","year":"2009","journal-title":"Am J Health Syst Pharm"},{"issue":"6","key":"10.1016\/j.jcrc.2019.07.008_bb0170","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/cc7093","article-title":"Clinical review: drug metabolism and nonrenal clearance in acute kidney injury","volume":"12","author":"Vilay","year":"2008","journal-title":"Crit Care"},{"issue":"8","key":"10.1016\/j.jcrc.2019.07.008_bb0175","first-page":"848","article-title":"Pharmacokinetics of ciprofloxacin and vancomycin in patients with acute renal failure treated by continuous haemodialysis","volume":"7","author":"Davies","year":"1992","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1016\/j.jcrc.2019.07.008_bb0180","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ijantimicag.2012.10.018","article-title":"Continuous infusion of vancomycin in septic patients receiving continuous renal replacement therapy","volume":"41","author":"Covajes","year":"2013","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"10.1016\/j.jcrc.2019.07.008_bb0185","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.jcrc.2019.07.008_bb0190","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1128\/AAC.01602-07","article-title":"Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity","volume":"52","author":"Lodise","year":"2008","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0883944119302217?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0883944119302217?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:41:10Z","timestamp":1760125270000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0883944119302217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":38,"alternative-id":["S0883944119302217"],"URL":"https:\/\/doi.org\/10.1016\/j.jcrc.2019.07.008","relation":{},"ISSN":["0883-9441"],"issn-type":[{"value":"0883-9441","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimal vancomycin dosing regimens for critically ill patients with acute kidney injury during continuous renal replacement therapy: A Monte Carlo simulation study","name":"articletitle","label":"Article Title"},{"value":"Journal of Critical Care","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcrc.2019.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}